Author

Hui-Cong Zhou

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Recent advances in tumor-activated prodrug nanoparticles for cancer immunotherapy

Numerous therapeutic agents have been demonstrated to initiate antitumor immune responses, thereby driving significant progress in cancer immunotherapy. However, clinical translation is severely limited by persistent challenges, including systemic toxicity, the immunosuppressive tumor microenvironment (TME), and low na...

Guan-Ran Wang, Kun Du, Di-Kai Sun et al. · Frontiers in Immunology · 0 citations

Sep 2026

Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy

Chemo-immunotherapy is limited by the poor bioavailability, nonspecific distribution, and systemic toxicity of free drugs. Here, we develop a reactive oxygen species (ROS)-responsive prodrug strategy by conjugating paclitaxel (PTX) and the TLR7/8 agonist resiquimod (R848) with a phenylboronic ester (PBE) moiety to ge...

Lu-Yao Wang, Zhao-Fan Yang, Yuan-Zhen Su et al. · Nano letters (Print) · 0 citations